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Abstract
Background: The biological effects of CD24 (FL-80) cross-linking on breast cancer cells have not
yet been established. We examined the impact of CD24 cross-linking on human breast cancer cell
line MCF-7.
Methods: MCF-7 and MDA-MB-231 cells were treated with anti-rabbit polyclonal IgG or anti-
human CD24 rabbit polyclonal antibodies to induce cross-linking, and then growth was studied.
Changes in cell characteristics such as cell cycle modulation, cell death, survival in three-
dimensional cultures, adhesion, and migration ability were assayed after CD24 cross-linking in
MCF-7.
Results: Expression of CD24 was analyzed by flow cytometry in MDA-MB-231 and MCF-7 cells
where 2% and 66% expression frequencies were observed, respectively. CD24 cross-linking
resulted in time-dependent proliferation reduction in MCF-7 cells, but no reduction in MDA-MB-
231 cells. MCF-7 cell survival was reduced by 15% in three-dimensional culture after CD24 cross-
linking. Increased MCF-7 cell apoptosis was observed after CD24 cross-linking, but no cell cycle
arrest was observed in that condition. The migration capacity of MCF-7 cells was diminished by
30% after CD24 cross-linking.
Conclusion:  Our results showed that CD24 cross-linking induced apoptosis and inhibited
migration in MCF-7 breast cancer cells. We conclude that CD24 may be considered as a novel
therapeutic target for breast cancer.
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Background
CD24 is expressed in hematopoietic cell types, including
B-cell precursors and neutrophils [1], and is also conven-
tionally used as a differentiation marker for keratinocytes
[2]. Accumulating evidence supports a role for CD24 in a
variety of malignancies, including B-cell lymphoma, renal
cell carcinoma, small-cell and non small-cell lung carci-
noma, nasopharyngeal carcinoma, hepatocellular carci-
noma, bladder carcinoma, epithelial ovarian cancer and
breast cancer [3].
CD24, designated 'heat-stable antigen' (HSA) in mice, is a
glycosylated cell-surface protein linked to the membrane
via a glycosyl-phosphatidylinositol (GPI) anchor [4].
CD24 has several potential N- and O-linked glycosylation
sites, which act as ligands for P-selectin [4].
CD24 is involved in cellular adhesion processes and sig-
nalling pathways in cancer cells that are dependent on
interactions with P-selectin [4]. Moreover, CD24-medi-
ated binding to P-selectin on endothelial cells and plate-
lets may facilitate the exit of tumor cells from the
bloodstream and potentiate metastasis [3]. In P-selectin-
deficient mice, diminished tumor growth and metastasis
is observed, compared with wild-type animals [5]. More-
over, CD24 over-expression is associated with invasive-
ness in urothelial carcinoma [6] and with migration and
invasion in gliomas [7]. These studies collectively imply
that CD24 might play an important role in tumorigenesis
and in the progression of cancer. Moreover, CD24 expres-
sion is suggested to be a marker of poor prognosis in var-
ious cancers, including breast carcinoma [8]. In breast
cancer, CD24 mediates progression, metastasis, and roll-
ing of tumor cells through interactions with P-selectin [9].
Additionally, CD24 function may be related to tamoxifen
resistance [10]. In this study, MCF-7 cells were used as a
general breast cancer cell model, based on the fact that
these cells are derived from a pleural effusion from a
patient with metastatic breast carcinoma [11]. MCF-7 cells
are adherent, and they aggregate into clusters under stand-
ard culture conditions to form duct like structures that
mimic luminal structures observed in under three-dimen-
sional culture conditions [12]. For this reason, MCF-7
cells have primarily been used as model of the luminal
breast cancer cell type, which express CK8/18 [13], CK19
[14], CD24 [15] and the estrogen receptor [16], but not
vimentin [11].
Recently, CD24 was recommended as a prognostic indica-
tor of poor patient survival in breast cancer [17]. It is
known that CD24 mRNA becomes unregulated after
amino acid starvation in MCF-7 cells and that the CD24
protein is expressed more than 80% in MCF-7 cells [15].
For this reason it is suggested that CD24 may play an
important role in the progression and metastasis of
human breast cancer [8,18].
The aim of this study was to further clarify the role of
CD24 in breast cancer cell growth using a cross-linking
approach. Changes in viable cell number, on adhesion
and migration abilities, and in cell growth and death were
assessed. We did to study directly impact on cross-linking
with CD24 (FL-80) antibody in MCF-7 human breast can-
cer cell line.
Methods
Cell culture
Unless otherwise specified, all reagents were purchased
from Sigma (St. Louis, MO). MDA-MB-231 and MCF-7
cell lines were cultured in Dulbecco's modified Eagle's
medium (DMEM) containing 10% fetal bovine serum
(FBS). For the anchorage-dependent culture, 5×105 cells
were seeded on a tissue culture dish (Falcon, San Jose,
CA). Cells were incubated at 37°C in a humidified atmos-
phere containing 5% CO2. Photographs were obtained
with an inverted system microscope (IX51 model)
equipped with a DP50 camera system (Olympus, Tokyo,
Japan).
CD24 expression in breast cell lines
To detach MDA-MB-231 and MCF-7 cells, cultures were
trypsinized for 3 min to minimize growth inhibition, and
detachment was monitored with a phase-contrast micro-
scope. After visual identification of detached cells, 5 ml of
medium containing serum was added to the culture for
trypsin inactivation. Cells were collected by centrifuga-
tion, and washed with 5 ml of PBS. Following a second
centrifugation step, pellets were resuspended in 500 µl
total volume with the appropriate amounts of antibodies
and supplement of PBS. The PE anti-human CD24 anti-
body (BD Pharmingen, NJ, USA) was applied according to
the manufacturer's manual. After antibody binding for 25
min at room temperature, cells were rinsed three times
with PBS and flow cytometry analyses were performed in
triplicate using a FACSCalibur system (Becton & Dickin-
son, San Jose, CA).
Assessment of changes in proliferation of MDA-MB-231 
and MCF-7 cells upon CD24 cross-linking
For each line, 5×105 cells were seeded with DMEM con-
taining 10% FBS and after 24 h, they were washed twice
with PBS. Fresh DMEM+10% FBS was added to the dish,
and CD24 was cross-linked with anti-rabbit polyclonal
IgG antibody and anti-human CD24 (FL-80) rabbit poly-
clonal antibody (Santa Cruz Biotechnology, Franklin
Lakes, NJ). Rabbit-polyclonal anti-CD24 (FL-80) anti-
body was raised against amino acids 1–80, representing
full length CD24 of human origin. For each condition, theBMC Cancer 2008, 8:118 http://www.biomedcentral.com/1471-2407/8/118
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number of viable cells was estimated by trypan blue stain-
ing.
Three-dimensional matrigel culture, and MTT assays
For a three-dimensional culture, a millicell (millipore,
Billerica, MA, USA) of 3 µm pore size was coated with 5
mg/ml matrigel (BD Pharmingen, NJ, USA) on a 6-well
plate at 37°C for 1 h. MCF-7 cells were trypsinized and
seeded onto millicells in a dose dependent manner of
1×105, 3×105, or 5×105 cells at 37°C for 24 h. After 24 h,
cells cross-linked with anti-rabbit polyclonal IgG (500 ng/
ml) or anti-human CD24 (FL-80) rabbit polyclonal anti-
body (500 ng/ml) at 37°C for 72 h, then the media was
removed. 100 µl of MTT reagents (5 mg/ml) were added
to each millicell, whch was incubated at 37°C for 3 h and
the media was removed. 200 µl of dimethylsulphoxide
(DMSO) was then added to each millicell with shaking for
10 min and the absorbance was measured spectrophoto-
metrically at 595 nm.
Cell cycle analysis and Annexin V staining
After cross-linking for 72 h, the MCF-7 culture was har-
vested, where cells were fixed in 70% ethanol for 1 h, and
washed with PBS. Cells were then treated with 100 µg/ml
RNase A for 1 h at 37°C, followed by 25 µg/ml propidium
iodide solution. Flow cytometry was then performed in
triplicate for each experiment on a FACSCalibur system
(Becton & Dickinson, San Jose, CA). Annexin V staining
was done according to the manufacturer's protocol (BD
Pharmingen, NJ, USA). MCF-7 cells were washed with PBS
and trypsinized. After centrifugation, cells were washed
twice with cold PBS, and resuspended in binding buffer
(10 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM
MgCl2, 1.8 mM CaCl2) at a concentration of 1×106 cells/
ml. An aliquot (100 µl) of the solution containing 1 × 105
cells was transferred to a 5 ml culture tube, and 5 µl each
of Annexin V-FITC and PI were added. After vortexing,
cells were incubated for 15 min at room temperature
(25°C) in the dark, and 400 µl of 1× binding buffer was
added to each tube. Flow cytometry was performed on a
FACSCalibur system (Becton & Dickinson, San Jose, CA)
within 1 h.
Adhesion assay
For adhesion assay, a 96-well plate was coated with type I
collagen (10 µg/ml) at 37°C for 1 h, washed twice with
PBS, and blocked with 10% FBS in PBS. MCF-7 cells were
seeded and incubated with anti-rabbit polyclonal IgG
(500 ng/ml) or anti-human CD24 rabbit polyclonal anti-
body (500 ng/ml) at 37°C for 24 h. After 24 h, MCF-7
cells were washed twice with PBS and trypsinized, then
seeded at 2×104/well and incubated at 37°C incubator for
24 h. Adherent cells were fixed with 3.7% paraformalde-
hyde at room temperature for 20 min, and cells were air-
dried for 5 min, followed by staining with 0.1% crystal
violet in methanol at room temperature for 45 min. Cells
were washed three times with PBS, and rinsed with 0.1 M
sodium citrate at room temperature for 30 min. The
absorbance of the resulting solution was measured at 595
nm.
Migration assay
The migration assay was performed following the manu-
facturer's protocol (BD Pharmingen, NJ, USA). MCF-7
cells were pre-treated with anti-rabbit polyclonal IgG (500
ng/ml) or anti-human CD24 rabbit polyclonal antibody
(500 ng/ml) at 37°C for 24 h. 2×104/well cells were
seeded onto the upper side of a transwell chamber (BD
Pharmingen, NJ, USA) and incubated at 37°C for 24 h.
Cells from the upper side of the transwell were then
scraped off mechanically, fixed with 100% methanol at
room temperature for 2 min and stained with 1% toluid-
ine blue in 1% borax solution at room temperature for 2
min and then counted with an inverted system micro-
scope.
Statistical analysis
All data were compiled from a minimum of three replicate
experiments. Data for statistical analysis were expressed as
the mean ± standard error. Comparison of results from
treated versus control cells was done using t-stests. p val-
ues of less than 0.05 were considered statistically signifi-
cant.
Results
CD24 expression in MDA-MB-231 and MCF-7 cells
Expression of CD24 was analyzed in MDA-MB-231 and
MCF-7 cells by flow cytometry, which revealed that 2% of
MDA-MB-231 cells and 66% of MCF-7 cells expressed
CD24 (Fig. 1). Based on this result, we selected MDA-MB-
231 as negative control and MCF-7 as an experimental cell
line for examining the effect of CD24 cross-linking on the
growth of breast cancer cells.
Proliferation of control and MCF-7 cells upon CD24 cross-
linking
72 h after cross-linking, the number of viable cells was
counted to analyze the effects of cross-linking on cell
growth. MCF-7 cell viability did not change after cross-
linking with 500 ng/ml anti-rabbit polyclonal IgG. How-
ever, cell viability after 72 h was reduced by 75% and 96%
at antibody concentrations of 1 µg/ml and 2 µg/ml,
respectively (Fig. 2A). We also examined cell growth in
five different culture media: culture medium without dis-
tilled water, culture medium with 0.025% distilled water,
distilled water with 0.00025% sodium azide, distilled
water with 0.00025% gelatin, and distilled water with
0.00025% PBS. We did not find difference in cell growth
in each culture condition (Data not shown). Accordingly,
500 ng/ml was selected as the dose of anti-rabbit polycloBMC Cancer 2008, 8:118 http://www.biomedcentral.com/1471-2407/8/118
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CD24 expression in MDA-MB-231 and MCF-7 cells by FACS (%) Figure 1
CD24 expression in MDA-MB-231 and MCF-7 cells by FACS (%). MDA-MB-231 and MCF-7 cells were cultured in 
DMEM containing 10% FBS for 72 h. Flow cytometry analysis was performed with PE anti-human CD24 antibody on a FACS-
Calibur system. A representative result is shown.
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Viability of MDA-MB-231 and MCF-7 cells after CD24 cross-linking Figure 2
Viability of MDA-MB-231 and MCF-7 cells after CD24 cross-linking. A) MCF-7 cross-linked with anti-rabbit polyclonal 
IgG in a dose dependent manner for 72 h. B) MDA-MB-231 cells were cross-linked with 500 ng/ml anti-rabbit polyclonal IgG or 
anti-human CD24 rabbit polyclonal antibody for 72 h. C). MCF-7 cells were cross-linked with 500 ng/ml anti-rabbit polyclonal 
IgG antibody or anti-human CD24 rabbit polyclonal antibody in a time dependent manner for 120 h. A-B) Relative cell survival 
rate is shown as percent survival versus control cells after cross-linking with anti-rabbit polyclonal IgG. C) MCF-7 cell survival 
is shown versus control cell survival when CD24 was cross-linked with anti-rabbit polyclonal IgG. Data represent means of at 
least three independent experiments and standard errors of the means. *, p value of less than 0.05 **, p value of less than 0.01.
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nal IgG that exerted no effect on viability. MDA-MB-231
and MCF-7 cells were treated with 500 ng/ml anti-rabbit
polyclonal IgG or 500 ng/ml anti-human CD24 rabbit
polyclonal antibody. There was no change in MDA-MB-
231 cell growth (Fig. 2B). In contrast, MCF-7 cell growth
decreased by 4%, 14%, 46%, 50%, and 62% at time-
points of 24 h, 48 h, 72 h, 96 h, and 120 h, respectively
(Fig. 2C).
Inhibition of growth after CD24 cross-linking in three-
dimensional culture
Three-dimensional culture using matrigel was predicted
to be a useful method for confirming the effect of cross-
linking  in vitro. We examined growth inhibition after
CD24 cross-linking using matrigel containing ECM. MCF-
7 cells were cross-linked with anti-rabbit polyclonal IgG
and anti-human CD24 rabbit polyclonal antibody at the
500 ng/ml dosage for 72 h. When cultured on top of
three-dimensional matrigel, MCF-7 cells cross-linked with
anti-human CD24 rabbit polyclonal antibody decreased
15% compared to cells cross-linked with anti-rabbit poly-
clonal IgG (Fig. 3).
Cell cycle and apoptosis analyses after CD24 cross-linking
We observed a decrease in cell number after CD24 cross-
linking. To determine whether the cause of decreased cell
MCF-7 cell growth in three-dimensional culture Figure 3
MCF-7 cell growth in three-dimensional culture. 1×105, 3×105, and 5×105 cells were cultured in DMEM containing 10% 
FBS in the three-dimensional matrigel (5 mg/ml) for 24 h and then CD24 was cross-linked with 500 ng/ml anti-rabbit polyclonal 
IgG or anti-human CD24 rabbit polyclonal antibody for 72 h. Cell viability in three-dimensional culture was examined by MTT 
assay. The data are shown as the absorbance of MCF-7 survival versus the control cell survival after CD24 cross-linking with 
anti-rabbit polyclonal IgG. Means of at least three independent experiments are compared and standard errors are shown. *, p 
value of less than 0.05.
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number was cell cycle arrest or apoptosis, we analyzed
DNA content with propidium iodide solution and
annexin V by flow cytometry. Stained DNA contents after
CD24 cross-linking were similar in each cell type com-
pared to after cross-linking with anti-rabbit polyclonal
IgG (Fig. 4). In the apoptosis assay, cell population
decreased by 10% and 26% at 72 h and 96 h, respectively,
exhibiting increased apoptosis after CD24 cross-linking
(Fig. 5A,B).
Effects of CD24 cross-linking on MCF-7 cell adhesion and 
migration
We assumed that CD24 was a cell adhesion molecule in
MCF-7 cells. MCF-7 was pre-treated with anti-rabbit poly-
clonal IgG or anti-human CD24 rabbit polyclonal anti-
body (500 ng/ml) for 24 h. The adhesion capacity of
harvested MCF-7 cells after CD24 cross-linking was not
significantly reduced (Fig. 6A), but the number of migrat-
ing cells was reduced by 30% (Fig. 6B).
Discussion
CD24 is important for progression, migration, and metas-
tasis of human breast cancer [8]. However, the specific
functions of CD24 in breast cancer are unclear. Here, we
showed that CD24 cross-linking is sufficient to inhibit
tumor growth (Fig. 2C), and migration (Fig. 6B) in MCF-
7 breast cancer cells. Additionally, apoptosis increased
upon CD24 cross-linking (Fig. 5).
Our results are in agreement with previous findings when
Suzuki  et al. [19] reported that CD24 cross-linking
induced apoptosis in a human B-cell subset during the
early activation stage through interactions with glycoli-
pid-enriched membrane domains. Taguchi et al. [20]
demonstrated that apoptosis observed upon cross-linking
CD24 did not result from non-specific binding of either
mouse immunoglobulin or secondary rabbit polyclonal
anti-mouse immunoglobulin antibody, but from treat-
ment with a combination of anti-CD24 and rabbit anti-
mouse immunoglobulin antibodies in KM-3 pro-B cells.
To confirm that the apoptosis observed upon cross-link-
ing of CD24 was not resulting from the non-specific bind-
ing of secondary rabbit polyclonal antibodies, MCF-7
cells were cross-linked with anti-human CD24 (SN3)
mouse monoclonal antibody raised against NALM-1
human pre-B leukemia cell line. Effect of cross-linking
with anti-human CD24 (SN3) mouse monoclonal anti-
body was similar to what was observed anti-human CD24
(FL-80) rabbit polyclonal antibody (Additional files. 2,
3). Several analogous reports documented proliferation
and apoptosis in human B-cells [19] and murine thymo-
cytes [21] after CD24 cross-linking.
In contrast to our findings, Schabath and colleagues
showed that MDA-MB-231 cells (used as a control in this
study) transfected to express CD24 had reduced migration
and tumor growth in NOD/SCID mice [22]. We cross-
linked CD24 in MCF-10A breast cells expressing CD24
and observed inhibited growth in the CD24 expressing
cells (Additional files. 1), similar to what was observed in
MCF-7 cells.
We found that CD24 cross-linking exhibited an inhibitory
effect on breast cancer cell growth in the three-dimen-
Changes in cell cycle after CD24 cross-linking 72 h Figure 4
Changes in cell cycle after CD24 cross-linking 72 h. The cell cycle was analyzed by FACS after DNA staining with pro-
pidium iodide and a representative experiment (from three total) is shown.
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sional culture system. In agreement with our findings,
Wang et al. [23] reported a reduction in T-cell prolifera-
tion upon blockage with an anti-HSA antibody. Moreo-
ver, cross-linking of CD24 induced apoptosis in murine
thymocytes [21]. Jung and colleagues [21] demonstrated
that apoptosis triggered by CD24 cross-linking results in
the generation of reactive oxygen species (ROS), and that
the release of apoptosis inducing factor (AIF) does not
lead to caspase activation in murine thymocytes.
Migration capacities of MCF-7 cells were reduced by 30%
after CD24 cross-linking. Our results further indicate that
CD24 is involved in migration in MCF-7 cells, and imply
that tumor progression can be inhibited by CD24 cross-
linking (Fig. 6B). Using in vitro migration assays
(matrigel) and in vivo immunohistochemical staining,
Senner et al. [7] have found, in a rat model, that CD24-
positive gliomas are more aggressive than CD24 negative
implants, but did not observe a greater migration rate of
CD24-positive cells in matrigel assays, which is in con-
cordance with our data. CD24 is an adhesion molecule [2]
and during tumor progression, adhesion to the extracellu-
lar matrix (ECM) is the initial step for invasion and metas-
tasis [24]. In our study the adhesion of MCF-7 cells was
Changes in apoptosis after CD24 cross-linking Figure 5
Changes in apoptosis after CD24 cross-linking. A) Cross-linking for 72 h. B) Cross-linking for 96 h. Cells were stained 
with FITC-conjugated annexin V in a buffer containing propidium iodide and analyzed by flow cytometry. For each group of 
cells, the percentage of survival is shown in the lower left quadrant, where both in annexin V and propidium iodide levels are 
low. One of three representative experiments is presented.
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reduced slightly, but not significantly after CD24 cross-
linking.
Interestingly, we observed variable expression rates of
CD24 in both control and MCF-7 cells. Figure 1 depicts
CD24 expression in 2% of control cells and 66% of MCF-
7 cells. However, expression levels of CD24 in MCF-7 cells
ranged from 66% to 98%, depending on the passage
number and culture conditions, including culture
medium serum composition (data not shown). A number
of reports show that alterations in protein expression are
dependent on the culture environment. For instance,
serum in MCF-10A cell culture plays an important role in
CD24 expression [11]. Estrogen-receptor expression is
altered in MCF-7 and BT474 cells depending on the pas-
sage number [25].
Recently, CD44+CD24-/low lineage-cells were implicated in
breast cancer initiated tumorigenesis in NOD/SCID mice
[26]. This work suggested that the tumor initiating cells
were cancer stem cells. Furthermore, early cancer cells
detected in bone marrow of breast cancer patients were
observed to have breast cancer stem sell phenotype [27],
but the frequency of CD44+/CD24-/low cells in breast can-
cer tissue was not correlated with clinical outcome [28].
CD24 was suggested as a marker of luminal cells in the
breast [29], and a previous report indicated the existence
of progenitor cells in luminal epithelia which could be
reflective of myoepithelial cells [30]. On the other hand,
normal stem cells have been isolated using CD24, CD29,
and CD49f in mouse mammary glands [31,32], so a sin-
gle, definitive breast cancer stem cell marker has yet to be
defined.
Conclusion
In conclusion, we demonstrated that CD24 cross-linking
induced apoptosis and inhibited migration ability in
MCF-7 human breast cancer cells. It is possible that CD24
in vivo may be a novel target for breast cancer treatment.
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Effects of CD24 cross-linking on the adhesion and migration capacity of MCF-7 cells Figure 6
Effects of CD24 cross-linking on the adhesion and migration capacity of MCF-7 cells. A) Relative adhesion rate in 
the data is shown as percent adherent cells versus control cells where CD24 was cross-linked with anti-rabbit polyclonal IgG. 
B) Relative migrating cell rate is shown as percent migrating cells versus control cells where CD24 was cross-linked with anti-
rabbit polyclonal IgG. *, p value of less than 0.05.
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